Free Trial

ImmunoPrecise Antibodies (IPA) Competitors

ImmunoPrecise Antibodies logo
$2.16 -0.15 (-6.49%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$2.23 +0.07 (+3.43%)
As of 07/25/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IPA vs. ARCT, BNTC, GOSS, CMPS, PRTA, ALT, AURA, RNAC, CAPR, and AMRN

Should you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Arcturus Therapeutics (ARCT), Benitec Biopharma (BNTC), Gossamer Bio (GOSS), COMPASS Pathways (CMPS), Prothena (PRTA), Altimmune (ALT), Aura Biosciences (AURA), Cartesian Therapeutics (RNAC), Capricor Therapeutics (CAPR), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry.

ImmunoPrecise Antibodies vs. Its Competitors

Arcturus Therapeutics (NASDAQ:ARCT) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

In the previous week, ImmunoPrecise Antibodies had 2 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 4 mentions for ImmunoPrecise Antibodies and 2 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.94 beat ImmunoPrecise Antibodies' score of 0.66 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcturus Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ImmunoPrecise Antibodies
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Arcturus Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500.

ImmunoPrecise Antibodies has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$152.31M2.66-$80.94M-$2.53-5.91
ImmunoPrecise Antibodies$24.00M4.12-$20.13M-$1.16-1.86

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 16.6% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Arcturus Therapeutics has a net margin of -47.47% compared to ImmunoPrecise Antibodies' net margin of -190.76%. Arcturus Therapeutics' return on equity of -27.41% beat ImmunoPrecise Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcturus Therapeutics-47.47% -27.41% -19.01%
ImmunoPrecise Antibodies -190.76%-88.87%-49.26%

Arcturus Therapeutics currently has a consensus target price of $54.00, indicating a potential upside of 261.45%. ImmunoPrecise Antibodies has a consensus target price of $4.00, indicating a potential upside of 85.19%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than ImmunoPrecise Antibodies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
ImmunoPrecise Antibodies
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Arcturus Therapeutics beats ImmunoPrecise Antibodies on 12 of the 17 factors compared between the two stocks.

Get ImmunoPrecise Antibodies News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IPA vs. The Competition

MetricImmunoPrecise AntibodiesMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$105.72M$2.06B$5.70B$9.50B
Dividend YieldN/AN/A4.58%4.01%
P/E Ratio-1.8637.0728.1020.05
Price / Sales4.1211.21429.0189.19
Price / CashN/A55.2536.2258.56
Price / Book2.329.108.665.87
Net Income-$20.13M-$63.59M$3.25B$258.55M
7 Day Performance24.86%3.16%4.22%3.73%
1 Month Performance94.59%10.15%10.51%11.75%
1 Year Performance154.12%6.21%34.40%18.03%

ImmunoPrecise Antibodies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IPA
ImmunoPrecise Antibodies
3.0175 of 5 stars
$2.16
-6.5%
$4.00
+85.2%
+156.2%$105.72M$24.00M-1.8680News Coverage
Upcoming Earnings
Gap Up
ARCT
Arcturus Therapeutics
2.1609 of 5 stars
$13.31
-3.4%
$54.00
+305.7%
-35.0%$360.98M$131.27M-5.26180
BNTC
Benitec Biopharma
1.7723 of 5 stars
$13.25
+3.7%
$23.83
+79.9%
+22.5%$347.81M$80K-8.7720
GOSS
Gossamer Bio
4.0075 of 5 stars
$1.53
+12.5%
$8.25
+439.2%
+68.8%$347.77M$114.70M-6.65180Positive News
High Trading Volume
CMPS
COMPASS Pathways
1.7447 of 5 stars
$3.71
+1.1%
$17.00
+358.2%
-42.0%$347.11MN/A-1.86120Upcoming Earnings
PRTA
Prothena
3.7494 of 5 stars
$6.43
+0.5%
$31.50
+389.9%
-73.1%$346.11M$137.94M-3.09130
ALT
Altimmune
2.0894 of 5 stars
$4.26
+2.9%
$18.20
+327.2%
-39.0%$345.53M$20K-3.3850
AURA
Aura Biosciences
2.4353 of 5 stars
$6.75
+5.5%
$22.00
+225.9%
-29.6%$339.32MN/A-3.5550News Coverage
Positive News
RNAC
Cartesian Therapeutics
2.3061 of 5 stars
$13.06
-2.0%
$40.00
+206.3%
-19.6%$338.91M$38.91M-0.2564News Coverage
CAPR
Capricor Therapeutics
2.7488 of 5 stars
$7.39
-3.3%
$22.56
+205.2%
+59.4%$337.58M$22.27M-5.20101Trending News
Gap Down
AMRN
Amarin
0.2424 of 5 stars
$16.10
-4.9%
$12.00
-25.5%
-2.7%$333.43M$228.61M-4.42360Positive News
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:IPA) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners